Advanced Cell Technology (ACT) gained rights to the commercial use of human embryonic stem cells (hESCs) for human therapies, with the exception of neuronal, pancreatic beta cells, and cardiac applications from Wisconsin Alumni Research Foundation. This expanded, nonexclusive commercialization agreement also enables ACT to market a broad array of research products.
The deal enhances ACT’s existing patent estate through the commercial access to an additional 150 stem cell technology patents and patent applications.
"We believe that the expanded license will afford our company greater flexibility and accelerate the process of bringing ACT's therapeutic programs toward human clinical trials and, ultimately, to commercial adoption and bedside use." says Michael D. West, Ph.D., president and CSO.
"The combination of these technologies and the rapidly growing pipeline coming from our ACTCellerate platform lead us to believe that other clinical applications, in addition to our current target indications, are feasible. These additional therapies include treatment for disorders of the endocrine, craniofacial, muscle, bone, cartilage, liver, kidney, and respiratory systems."